Novartis and Stemline Therapeutics will likely learn this week whether the EU marketing applications they plan to file for their investigational treatments for Cushing's syndrome and blastic plasmacytoid dendritic cell neoplasm (BPDCN) respectively will be granted fast-track review.
The companies’ requests for regulatory review via the European Medicines Agency’s accelerated assessment procedure are due to be considered by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?